Literature DB >> 23242540

A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States.

Patti E Gravitt1, Anne F Rositch, Michelle I Silver, Morgan A Marks, Kathryn Chang, Anne E Burke, Raphael P Viscidi.   

Abstract

BACKGROUND: Cohort effects, new sex partnerships, and human papillomavirus (HPV) reactivation have been posited as explanations for the bimodal age-specific HPV prevalence observed in some populations; no studies have systematically evaluated the reasons for the lack of a second peak in the United States.
METHODS: A cohort of 843 women aged 35-60 years were enrolled into a 2-year, semiannual follow-up study. Age-specific HPV prevalence was estimated in strata defined by a lower risk of prior infection (<5 self-reported lifetime sex partners) and a higher risk of prior infection (≥ 5 lifetime sex partners). The interaction between age and lifetime sex partners was tested using likelihood ratio statistics. Population attributable risk (PAR) was estimated using Levin's formula.
RESULTS: The age-specific prevalence of 14 high-risk HPV genotypes (HR-HPV) declined with age among women with <5 lifetime sex partners but not among women with ≥ 5 lifetime sex partners (P = .01 for interaction). The PAR for HR-HPV due to ≥ 5 lifetime sex partners was higher among older women (87.2%), compared with younger women (28.0%). In contrast, the PAR associated with a new sex partner was 28% among women aged 35-49 years and 7.7% among women aged 50-60 years.
CONCLUSIONS: A lower cumulative probability of HPV infection among women with a sexual debut before the sexual revolution may be masking an age-related increase in HPV reactivation in the United States.

Entities:  

Mesh:

Year:  2012        PMID: 23242540      PMCID: PMC3532829          DOI: 10.1093/infdis/jis660

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women.

Authors:  Morgan A Marks; Raphael P Viscidi; Kathryn Chang; Michelle Silver; Anne Burke; Roslyn Howard; Patti E Gravitt
Journal:  Cytokine       Date:  2011-10-19       Impact factor: 3.861

Review 3.  The known unknowns of HPV natural history.

Authors:  Patti E Gravitt
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

4.  Prevalence of human papillomavirus antibodies in males and females in England.

Authors:  Sarika Desai; Ruth Chapman; Mark Jit; Tom Nichols; Ray Borrow; Michael Wilding; Christina Linford; Catherine M Lowndes; Anthony Nardone; Richard Pebody; Kate Soldan
Journal:  Sex Transm Dis       Date:  2011-07       Impact factor: 2.830

5.  Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.

Authors:  Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

6.  Incidence of in situ and invasive vulvar cancer in the US, 1998-2003.

Authors:  Mona Saraiya; Meg Watson; Xiaocheng Wu; Jessica B King; Vivien W Chen; Jennifer S Smith; Anna R Giuliano
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

7.  Understanding the burden of human papillomavirus-associated anal cancers in the US.

Authors:  Djenaba A Joseph; Jacqueline W Miller; Xiaocheng Wu; Vivien W Chen; Cyllene R Morris; Marc T Goodman; Jose M Villalon-Gomez; Melanie A Williams; Rosemary D Cress
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

8.  The correlation between human papillomavirus positivity and abnormal cervical cytology result differs by age among perimenopausal women.

Authors:  Anne F Rositch; Michelle I Silver; Anne Burke; Raphael Viscidi; Kathryn Chang; Cindy M P Duke; Wen Shen; Patti E Gravitt
Journal:  J Low Genit Tract Dis       Date:  2013-01       Impact factor: 1.925

9.  Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.

Authors:  S Deblina Datta; Laura A Koutsky; Sylvie Ratelle; Elizabeth R Unger; Judith Shlay; Tracie McClain; Beth Weaver; Peter Kerndt; Jonathan Zenilman; Michael Hagensee; Cristen J Suhr; Hillard Weinstock
Journal:  Ann Intern Med       Date:  2008-04-01       Impact factor: 25.391

10.  Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3.

Authors:  Hannah P Yang; Rosemary E Zuna; Mark Schiffman; Joan L Walker; Mark E Sherman; Lisa M Landrum; Katherine Moxley; Michael A Gold; S Terence Dunn; Richard A Allen; Roy Zhang; Rodney Long; Sophia S Wang; Nicolas Wentzensen
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

View more
  50 in total

1.  Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection.

Authors:  Lauren Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2014-02-25       Impact factor: 5.226

2.  Sinecatechins Ointment, 15% for the Treatment of External Genital and Perianal Warts: Proceedings of an Expert Panel Roundtable Meeting.

Authors:  Gary Goldenberg; Maida Taylor; Brian Berman; Mark Kaufmann; William Abramovits; Joshua Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2016-03-01

3.  Human papillomavirus in older women: new infection or reactivation?

Authors:  Darron R Brown; Bree Weaver
Journal:  J Infect Dis       Date:  2012-12-12       Impact factor: 5.226

4.  Human Papillomavirus DNA Detection in Older Women-Implications for Cancer Screening and Prevention.

Authors:  Aaron C Ermel; Kenneth H Fife
Journal:  J Infect Dis       Date:  2016-03-23       Impact factor: 5.226

5.  [Extragenital, disseminated infection with human papillomaviruses : Therapeutic response through vaccination with HPV].

Authors:  L Wiskemann; B Durani; W Hartschuh
Journal:  Hautarzt       Date:  2018-03       Impact factor: 0.751

6.  High-risk human papillomavirus viral load and persistence among heterosexual HIV-negative and HIV-positive men.

Authors:  Mary K Grabowski; Ronald H Gray; David Serwadda; Godfrey Kigozi; Patti E Gravitt; Fred Nalugoda; Steven J Reynolds; Maria J Wawer; Stephen Watya; Thomas C Quinn; Aaron A R Tobian
Journal:  Sex Transm Infect       Date:  2014-01-30       Impact factor: 3.519

7.  The Impact of Human Papillomavirus Infection on Skin Cancer: A Population-Based Cohort Study.

Authors:  Ming-Li Chen; James Cheng-Chung Wei; Shuo-Hsuan Wang; Hei-Tung Yip; Yao-Min Hung; Renin Chang
Journal:  Oncologist       Date:  2020-12-08

8.  Partner Human Papillomavirus Viral Load and Incident Human Papillomavirus Detection in Heterosexual Couples.

Authors:  Mary K Grabowski; Xiangrong Kong; Ronald H Gray; David Serwadda; Godfrey Kigozi; Patti E Gravitt; Fred Nalugoda; Steven J Reynolds; Maria J Wawer; Andrew D Redd; Stephen Watya; Thomas C Quinn; Aaron A R Tobian
Journal:  J Infect Dis       Date:  2015-11-23       Impact factor: 5.226

9.  Association of Chlamydia trachomatis infection with redetection of human papillomavirus after apparent clearance.

Authors:  Marcia L Shew; Aaron C Ermel; Bree A Weaver; Yan Tong; Wanzhu Tu; Laura M Kester; Cheryl Denski; J D Fortenberry; Darron R Brown
Journal:  J Infect Dis       Date:  2013-08-02       Impact factor: 5.226

10.  Cervical Cancer Incidence Among Elderly Women in Massachusetts Compared With Younger Women.

Authors:  Sarah Feldman; Erin Cook; Michelle Davis; Susan T Gershman; Amresh Hanchate; Jennifer S Haas; Rebecca B Perkins
Journal:  J Low Genit Tract Dis       Date:  2018-10       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.